A customer walks out of a Walgreens pharmacy store in Austin, Texas ReutersWalgreens has suspended contributions to the 147 Republican lawmakers who opposed the certification of president-elect Joe Biden. The pharmaceutical corporation Pfizer has also reportedly decided to also suspend contributions to those lawmakers for six months. The two corporations join Amazon, Marriott, AT&T and others in suspending donations to GOP lawmakers who tried to overturn the election. Some corporations are choosing to suspend all political donations instead of to just the senators and representatives who objected to Biden's certification. Visit Business Insider's homepage for more stories. After the violent pro-Trump riot on Capitol Hill last week, some businesses began cutting ties with President Donald Trump, while some corporations decided to suspend political donations to one or both political parties. Walgreens and Pfizer are two of the most recent companies to suspend PAC contributions to the 147 Republican lawmakers who opposed the certification of Democrat Joe Biden as the next president. Walgreens confirmed to Insider on Saturday that it has suspended contributions to the GOP members of congress who voted to overturn the election results. "Walgreens holds in high regard the role of government and the peaceful transition of
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Below are experts from the ProfNet network who are available to discuss timely issues in your coverage area. EXPERT ALERTS 5 Steps to Craft Your Own Plan for Financial Wellness How to Create Hope When Things Feel Ambiguous and Chaotic The Deeper Meaning Behind Your Relationship With Money 3 Tips to Reduce Volatility and Cultivate Calm CHANGE: 6 Steps to Resilience Wisdom Transform How You Respond to Stress With Internal Training Use Pre-Employment Testing to Avoid Costly Hiring Mistakes 5 Ways to Turn Seasonal Sad Into Seasonal Glad Attention, Intention, Attitude: 3 Mindful Ways to Deal With Anger Can You Put Your Press Kit on Your Website? Do You Have Postpartum Depression? Electric Pressure Cooker Safety Issues Wellness Tips How to Become a Better Listener Financial Advisors: Meet the F.L.I.P. It's Not Too Late to Start Resolutions for a Better Year Ahead 5 Biggest Threats to Retirement Security Exercise and Pregnancy: 5 Tips MEDIA JOBS Audience Interaction Producer, The Wall Street Journal - NY/Remote OTHER NEWS & RESOURCES 6 Writing Habits You Should Adopt in 2021 Blog Profiles: Relocation Blogs 5 Steps to Craft Your Own Plan for Financial WellnessStephanie MackaraAuthor, finance expert, JD, CDFAStephanie
02:19 AM Mosaic Acquisition a Hold Deutsche Bank 02:16 AM Vishay Intertechnology Underperform Bank of America Merrill Lynch 02:09 AM Spotify Sell Citigroup Corp. 02:05 AM NextCure Underperform Bank of America Merrill Lynch 02:02 AM American Equity Investment Life Outperform Raymond James Financial, Inc. 01:59 AM Tilray Neutral Cantor Fitzgerald 01:58 AM Chegg Buy Needham & Company, LLC 01:58 AM Intercept Pharmaceuticals Underperform Bank of America Merrill Lynch 01:53 AM Esperion Therapeutics Neutral Bank of America Merrill Lynch 01:50 AM Acacia Communications Neutral Rosenblatt 01:47 AM Centene Hold Jefferies & Company Inc. 01:42 AM AstraZeneca Buy Deutsche Bank 01:41 AM American Electric Power Sell Goldman Sachs 01:40 AM GlaxoSmithKline Hold Deutsche Bank 01:39 AM Aerovironment Hold Stifel, Nicolaus & Co., Inc. 01:39 AM Novartis Buy Deutsche Bank 01:37 AM Novo Nordisk (spons ADRs Buy Deutsche Bank 01:35 AM Stifel Financial Equal Weight Wells Fargo & Co 01:34 AM Premie a Underperform Credit Suisse 01:32 AM Healthways Underperform Credit Suisse 01:29
ANN ARBOR, Mich., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has completed production and genetic screening of its latest batch of spider silk silkworm eggs. These specialized silkworm eggs are now ready for shipment to Vietnam to restart commercial production. Production operations at the Company’s factory were suspended in March due to a mandatory shutdown, resulting from the global spread of COVID-19. During the COVID-19 quarantine, Kraig Labs’ U.S.-based team focused its efforts on improving the performance and genetics of its Dragon Silk strain of recombinant spider silk silkworms. Kraig Labs’ U.S. operations also used this time to scale up its supply of silkworm eggs to allow for a restart of its operations in Vietnam. “Our teams have done a fantastic job, making significant progress in our genetics, production readiness, and R&D,” said CEO and Founder, Kim Thompson. “We believe that these silkworm eggs that are now ready for shipment to our factory, represent the future of spider silk production.” To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news About Kraig Biocraft Laboratories, Inc. Kraig Biocraft Laboratories, Inc.
CALGARY, Alberta and HONG KONG, May 21, 2020 /CNW/ -- Crypto.com, the pioneering payments and cryptocurrency platform, today announced that it is preparing to roll out the MCO Visa Card program in Canada, following launches in Singapore (Oct 2018), the United States (July 2019) and Europe (April 2020). The MCO Visa* Card is a prepaid card that features high-end metal cards with no annual or monthly fees, airport lounge access for select cards, no-fee ATM withdrawals, contactless pay functionality, and no foreign transaction fees. Reservations for the MCO Visa Card may be made using the Crypto.com App which includes a three-minute customer onboarding process including ID verification. Using the App, customers are able to manage their card usage, transactions, and freeze or unfreeze their card with a single tap. The App also allows users to securely buy, sell, store, send, and track cryptocurrencies – allowing users to spend fiat currency converted from cryptocurrency without currency exchange fees. Notes: All MCO Visa Card transactions are denominated in fiat currency. All cryptocurrency exchanges to fiat currency take place before users may use their MCO Visa Card to transact on the Visa network. The MCO Prepaid Visa Card is issued by DC
03:20 AM WEX Neutral Bank of America Merrill Lynch 03:16 AM Shift4 Payment a Underperform Bank of America Merrill Lynch 03:13 AM Regions Financial Neutral Wedbush Morgan Securities Inc. 03:10 AM Range Resources Neutral Bank of America Merrill Lynch 03:00 AM Perrigo Company Sector Perform RBC Capital Markets 02:58 AM PepsiCo Evercore 02:56 AM Arlo Technologies Buy BWS Financial 02:51 AM PBF Energ a Underperform Bank of America Merrill Lynch 02:42 AM Magellan Health Services Equal Weight Stephens Inc. 02:36 AM Dr Pepper Snapple Group Evercore 02:31 AM NextEra Energy Neutral Credit Suisse 02:30 AM i3 Vertical a Underperform Bank of America Merrill Lynch 02:29 AM Stryker Outperform Credit Suisse 02:27 AM Huntington Ingalls Industries Hold Vertical Research 02:19 AM Horace Mann Educators Neutral Piper Sandler 02:16 AM DXC Technology Underperform Bank of America Merrill Lynch 02:12 AM Cabot Oil & Gas Underperform Bank of America Merrill Lynch 02:11 AM MarketAxess Neutral Rosenblatt 02:09 AM CME Grou a Sell Rosenblatt 02:01 AM
Apple CEO Tim Cook, Amazon CEO Jeff Bezos, Google CEO Sundar Pichai and Facebook CEO Mark Zuckerberg. ANGELA WEISS/AFP via Getty Images/Rich...
Alibaba’s headquarters in...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021. Presentation details: Date: Available starting on Friday, January 15 at 5:00 a.m. Pacific Time Title: A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients with advanced biliary tract cancers Lead Author: Milind Javle, M.D., University of Texas MD Anderson Cancer Center Poster Session: Hepatobiliary Cancer, Abstract 311 Additional meeting information and accepted abstracts can be found at the ASCO website www.asco.org. About Calithera Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives